MX2019015177A - Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas. - Google Patents

Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas.

Info

Publication number
MX2019015177A
MX2019015177A MX2019015177A MX2019015177A MX2019015177A MX 2019015177 A MX2019015177 A MX 2019015177A MX 2019015177 A MX2019015177 A MX 2019015177A MX 2019015177 A MX2019015177 A MX 2019015177A MX 2019015177 A MX2019015177 A MX 2019015177A
Authority
MX
Mexico
Prior art keywords
ethoxy
pyrimidin
acrylamide
dimethylamino
phenyl
Prior art date
Application number
MX2019015177A
Other languages
English (en)
Inventor
Nicholas Greco Michael
John Costanzo Michael
Peng Jirong
Lynn Wilde Victoria
Zhang Don
Alan Green Michael
Original Assignee
Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Inc filed Critical Beta Pharma Inc
Publication of MX2019015177A publication Critical patent/MX2019015177A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se divulgan una formulación farmacéutica de N-(2-(2-(dimetilamino) etoxi)-4-metoxi-5-((4-(1-metil-1H-indol-3-il)pirimidin-2-il)amino )fenil)acrilamida (compuesto 1), en particular la sal del ácido metanosulfónico de ella y métodos para usar la formulación farmacéutica para el tratamiento o la prevención de enfermedades o afecciones médicas mediadas a través de formas mutadas del receptor del factor de crecimiento epidérmico (EGFR), tales como diversos cánceres.
MX2019015177A 2017-06-16 2018-06-15 Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas. MX2019015177A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762521007P 2017-06-16 2017-06-16
PCT/US2018/037744 WO2018232235A1 (en) 2017-06-16 2018-06-15 Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof

Publications (1)

Publication Number Publication Date
MX2019015177A true MX2019015177A (es) 2020-02-07

Family

ID=64660336

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015177A MX2019015177A (es) 2017-06-16 2018-06-15 Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas.

Country Status (16)

Country Link
US (2) US11180478B2 (es)
EP (1) EP3638241B1 (es)
JP (2) JP7045726B2 (es)
KR (1) KR20200016969A (es)
CN (1) CN110799191B (es)
AU (1) AU2018283289B2 (es)
BR (1) BR112019026483A2 (es)
CA (1) CA3067044A1 (es)
CO (1) CO2019014350A2 (es)
EA (1) EA201992744A1 (es)
IL (1) IL271220A (es)
MX (1) MX2019015177A (es)
PH (1) PH12019502830A1 (es)
SG (1) SG11201911859QA (es)
TW (1) TW201904577A (es)
WO (1) WO2018232235A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202012312UA (en) * 2018-06-18 2021-01-28 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
CN110898026A (zh) * 2019-12-11 2020-03-24 倍而达药业（苏州）有限公司 包含bpi-7711的药用组合物及其制备方法
CN111100117B (zh) * 2019-12-18 2021-02-19 上海倍而达药业有限公司 氨基嘧啶类化合物甲磺酸盐的晶型a及其制备方法和应用
CN113387935B (zh) * 2021-07-23 2022-06-10 苏州雅深智慧科技有限公司 抑制三突变表皮生长因子受体酪氨酸激酶的化合物及用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL220952B1 (pl) 2002-01-22 2016-01-29 Warner Lambert Co 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
JP2009513623A (ja) 2005-10-28 2009-04-02 アーチ ファーマラブズ リミテッド 塩酸ジェムシタビンの改良された製造方法
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
EA032294B1 (ru) * 2007-07-30 2019-05-31 Арди Байосайенсиз, Инк. Способ получения полиморфной формы производного n-(ариламино)сульфонамида, фармацевтическая композиция, содержащая указанное производное, и способ лечения с помощью указанного производного
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
NZ625712A (en) 2009-11-27 2016-02-26 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
MX347218B (es) 2010-04-12 2017-04-20 Supernus Pharmaceuticals Inc Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
SG10201609324UA (en) * 2010-07-16 2017-01-27 Exelixis Inc C-met modulator pharmaceutical compositions
AU2012288626C1 (en) 2011-07-27 2015-09-17 Astrazeneca Ab 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as EGFR modulators useful for treating cancer
CN111170998B (zh) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
EP3229798A4 (en) * 2014-12-11 2018-05-30 Beta Pharma, Inc. Substituted 2-anilinopyrimidine derivatives as egfr modulators
CN104961731A (zh) 2015-02-05 2015-10-07 苏州晶云药物科技有限公司 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法
CN104910049B (zh) 2015-06-16 2016-06-29 苏州明锐医药科技有限公司 Azd9291中间体及其制备方法
BR112018072887A2 (pt) 2016-05-11 2019-03-06 Beta Pharma, Inc. método de tratamento de câncer de cérebro em um indivíduo, e utilização de um composto
WO2017218892A1 (en) * 2016-06-17 2017-12-21 Beta Pharma, Inc. Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof

Also Published As

Publication number Publication date
AU2018283289B2 (en) 2021-03-25
PH12019502830A1 (en) 2020-12-07
EP3638241A4 (en) 2020-10-07
US20200131152A1 (en) 2020-04-30
JP7045726B2 (ja) 2022-04-01
SG11201911859QA (en) 2020-01-30
CO2019014350A2 (es) 2020-04-24
CN110799191B (zh) 2023-05-26
TW201904577A (zh) 2019-02-01
CN110799191A (zh) 2020-02-14
AU2018283289A1 (en) 2020-01-02
IL271220A (en) 2020-01-30
EA201992744A1 (ru) 2020-05-27
EP3638241B1 (en) 2022-05-25
JP2022058492A (ja) 2022-04-12
CA3067044A1 (en) 2018-12-20
US11180478B2 (en) 2021-11-23
JP2020523376A (ja) 2020-08-06
WO2018232235A1 (en) 2018-12-20
EP3638241A1 (en) 2020-04-22
US20220153726A1 (en) 2022-05-19
KR20200016969A (ko) 2020-02-17
BR112019026483A2 (pt) 2020-07-14

Similar Documents

Publication Publication Date Title
PH12019502830A1 (en) Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CY1124680T1 (el) Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
CY1122549T1 (el) Παραγωγα καρβαζολης
MX2019001581A (es) Inhibidores de ssao de aminopirimidina.
PH12021550992A1 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors
MX2018000777A (es) Compuestos de quinazolina sustituido y su uso como inhibidores de proteinas kras, hras y/o nras mutantes g12c.
WO2016060443A3 (en) Compounds and compositions for modulating egfr mutant kinase activities
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
WO2014125408A3 (en) Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
PH12018502668A1 (en) Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
CY1123527T1 (el) Αντιφυματικος παραγοντας
HRP20100265T1 (hr) Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti
MX2018014232A (es) Formulacion farmaceutica.
MX2019004375A (es) Inhibidores de bromodominios.
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов
CY1116335T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν ν-(4(2-αμινο-3-χλωροπυριδιν-4-υλοξυ)-3-φθοροφαινυλ)-4-αιθοξυ-l-(4-φθοροφαινυλ)-2-οξο-1,2-διυδροπυριδιν-3-καρβοξαμιδιο
EA202092034A2 (ru) Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака